In addition, the epidermal growth factor receptor (EGFR) overexpression observed in the SEGAs and cortical tubers of TSC patients has opened the possibility of targeting the EGFR signalling pathway with afatinib. This evidence concerns the gene EGFR and tuberous sclerosis.